Ann: Response to ASX Query Letter, page-21

First 21 Last

Share
Profile

Follow
HelpfulHeath

139 Posts.

9

16/04/18

11:05

Post #: 32476504
Share
Originally posted by philips ↑

Cryptocurrencies are on their way back says Wall Street analyst

Good news for investors in the market for digital currencies.
The bear market for alt-coins, or alternative cyptocurrencies, is “largely over” according to a group of analysts at Fundstrat, the Wall Street research firm led by noted bitcoin bull Tom Lee.
Alt-coins generally refer to the more than 1000 cryptocurrency alternatives launched after the success of bitcoin. Examples include Litecoin, Ripple and Dogecoin.
For the most part, smaller cryptocurrencies have been stuck in a rout since the beginning of 2018. In total, the market for digital coins has shed more than $US500 billion of its value from an all-time high above $US800 billion at the beginning of the year.
Since then, Fundstrat has advised clients to stick with large-cap coins such as bitcoin and ether to weather the storm.
Recently, Lee said bitcoin would retest its highs close to $US20,000 set in December by July of 2018.
Now, it’s telling clients to get ready for the end of the alt-coin bear market. Here’s Fundstrat in a note out to clients on Tuesday:
“After a 75 per cent decline in Alt-coins since 1/13/18, our alt-coin indicator (“% of alt-coins rising >200% in past 90D, or 3X) now sits at 3 per cent, suggesting the bulk of the alt-coin retracement is done-in other words, we believe the alt-coin bear market is largely over.”

That doesn’t mean the firm is advising crypto-lovers to dive head first into their favourite alts just yet.

“While the bulk of the decline is behind us, a bull market for alt-coins, however, is not necessarily underway,” Fundstrat said.
According to the firm, alt-coins have historically gone through “purgatory periods” following a bear market, which have lasted as long as 231 days.
“Given this expected purgatory, we advise sticking with large-caps,” the firm said.
The firm’s top bets include bitcoin cash, bitcoin, and litecoin.

Expand

Still more questions I guess.

On the bright side crypto currencies are surging.
CHP Price at posting: 0.9¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

AUN

Cyclone signs MOU with Vale for development of Iron Bear play

ME1

Banshee's historic trenches prove rich in antimony and gold for GDM

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

AN1

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

EDE

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

LYN

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

First 21 Last

Add CHP (ASX) to my watchlist

Ann: Response to ASX Query Letter, page-21

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Cyclone signs MOU with Vale for development of Iron Bear play

Banshee's historic trenches prove rich in antimony and gold for GDM

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain